Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

Blood. 2019 May 30;133(22):2452-2455. doi: 10.1182/blood.2019896688. Epub 2019 Mar 27.

Authors

Inhye E Ahn¹, Neil Basumallik^{1

2}, Xin Tian³, Susan Soto¹, Adrian Wiestner¹

Affiliations

¹ Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
² Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY; and.
³ Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Multicenter Study
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Aged
Female
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
Male
Piperidines
Pyrazoles / administration & dosage*
Pyrazoles / adverse effects
Pyrimidines / administration & dosage*
Pyrimidines / adverse effects

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine